IL36R Inhibitors
1 drugsAbout IL36R
Interleukin-36 receptor (IL36R) is a protein involved in the IL-36 cytokine family signaling pathway, which mediates inflammatory responses.
Currently, there is no genetic evidence directly linking IL36R to specific diseases, representing an area for further research to identify novel therapeutic opportunities.
IL36R is targeted by one FDA-approved biologic drug, SPEVIGO, developed by Boehringer Ingelheim for a single indication.
Top IL36R Drugs
Boehringer Ingelheim is the only company with an approved drug targeting IL36R.
Low competition suggests high barriers to entry or limited perceived market opportunity.
IL36R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL36R, using biologic (other) modality.
The lack of small molecule or other modalities represents a whitespace opportunity for innovation.
IL36R Clinical Trials 29 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL36R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 20 | 12 | 7 | 1 | 63% |
| Phase 3 | 3 | 2 | 0 | 1 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IL36R Drug Approval Timeline (2022 - 2022)
The first and only drug, SPEVIGO, was approved in 2022.
Recent approval suggests growing interest, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL36R. A trial counts if an approved drug acting on IL36R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.